HER2+ 유방암

52개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved52 programs
AntibodyLimited DatastaleRochePhase 3

pertuzumab (Perjeta, pertuzumab [Perjeta])

Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase3#monoclonal-antibody#BreastCancer+1
Trials 3Status Active
ADCLimited DatastaleRochePhase 1

trastuzumab (Herceptin, trastuzumab-MCC-DM1)

Metastatic Breast Cancer · MET

#MET#ADC#Phase1#antibody-drug-conjugate#MetastaticBreastCancer+1
Trials 3Status Active
AntibodyLimited DatastaleNeovii BiotechPhase 2

ertumaxomab (ertumaxomab)

Metastatic Breast Cancer; Advanced Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#AdvancedBreastCancer+1
Trials 2Status Discontinued
AntibodyLimited DatastaleYuan YuanPhase 2

Balstilmab (Balstilmab)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase2#monoclonal-antibody#MetastaticTriple-NegativeBreastC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleSouth Eastern European Research…Phase 2

Capecitabine and Bevacizumab (Capecitabine and Bevacizumab)

Breast Cancer; Metastasis · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#Metastasis+1
Trials 1Status Active
AntibodyLimited DatastaleShandong Cancer Hospital and In…Phase 2

trastuzumab (Herceptin, Capecitabine,Trastuzumab, and Pertuzumab)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase2#monoclonal-antibody#Shandong
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Cryoablation Combined with Tirelizumab and Bevacizumab (Cryoablation Combined with Tirelizumab and Bevacizumab)

Metastatic Breast Cancer in the Liver · Metastatic Breast Cancer in the Liver

#MetastaticBreastCancerintheLiver#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
CGTLimited DatastaleEssen BiotechPhase 2

Dual-Target Antigen-Selected CAR-NK (Dual-Target Antigen-Selected CAR-NK)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EB-DT-CAR-NK (Dual-target CAR-NK cells, Dual-target CAR-NK cells (EB-DT-CAR-NK))

Breast Cancer (Locally Advanced or Metastatic); HER2-positive Breast Cancer · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSichuan UniversityPhase 1

Dual-targeting HER2 and PD-L1 CAR-T cells (Dual-targeting HER2 and PD-L1 CAR-T cells)

Peritoneal Carcinoma Metastatic; Pleural Effusion, Malignant · HER2

#HER2#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleEssen BiotechPhase 2

EB-SELECT Single-Target CAR-NK Cells (EB-SELECT Single-Target CAR-NK Cells)

Cancer; Breast Cancer · MET

#MET#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleBeijing BiotechPhase 2

EGFR/HER2 Dual-Target CAR-NK Cells (EGFR/HER2 Dual-Target CAR-NK Cells)

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma; Biomarker-positive EGFR/HER2- Expressing HNSCC · HER2

#HER2#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleNanogen Pharmaceutical Biotechn…Phase 3

Faceptor (Faceptor)

Breast Cancer Metastatic; Breast Cancer Recurrent · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase3#monoclonal-antibody#BreastCancerRecurrent+1
Trials 1Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of VirginiaPhase 2

pembrolizumab (Keytruda, HER2 BATs with Pembrolizumab)

Metastatic Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#MetastaticBreastCancer+1
Trials 1Status Recruiting
CGTLimited DatastaleThe Methodist Hospital Research…Phase 2

IL-12 gene therapy (IL-12 gene therapy)

Triple Negative Breast Cancer; Anthracycline-refractory TNBC · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Discontinued
ADCLimited DatastaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Megestrol Acetate + Trastuzumab Deruxtecan)

Advanced/Metastatic Breast Cancer; HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer · HER2

#HER2#ADC#Phase3#antibody-drug-conjugate#Advanced+3
Trials 1Status Recruiting
CGTLimited DatastaleImugene LimitedPhase 1

Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody (Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 3

ZRC-3277 (Pertuzumab, Pertuzumab (ZRC-3277))

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

trastuzumab (Herceptin, Pertuzumab + trastuzumab + metronomic chemotherapy)

Elderly Metastatic Breast Cancer Population · Elderly Metastatic Breast Cancer Populat

#ElderlyMetastaticBreastCancerPop#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active

2 / 3 pages

← PreviousNext →